TOKYO, Dec 18 (Reuters) - Japan’s Shionogi & Co said on Tuesday that it has applied to health regulators in the United States, Canada and Europe for approval of its HIV drug Dolutegravir. Shionogi developed Dolutegravir with a Viiv Healthcare, an AIDS drug joint venture between GlaxoSmithKline and Pfizer, in exchange for its rights to the drug.
The HIV drug is approved for use in japan
( z1 approve :ARG1 ( z2 use :ARG1 ( z3 drug :mod ( z4 disease :name ( z5 name :op "HIV" ) ) ) ) :location ( z6 country :name ( z7 name :op "Japan" ) ) )